BioSpace News Archive

Jazz Pharmaceuticals plc announced that the company will virtually participate in the following upcoming investor conferences.

Veracyte, Inc.Veracyte, Inc. announced financial results for the third quarter ended September 30, 2021.

Zymeworks Inc., a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, announced that Neil Josephson, M.D., who has been serving as the company’s interim Chief Medical Officer since May of this year, will transition to the permanent CMO position, effective November 15.

Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, reported financial results for the third quarter of 2021 and provided key business updates across the company’s clinical-stage pipeline of novel NMDA receptor modulators.

CONMED Corporation (NYSE: CNMD) today announced that Curt R. Hartman, Chair of the Board, President, and Chief Executive Officer, and Todd W. Garner, Executive Vice President and Chief Financial Officer, will participate in a presentation at the Stifel 2021 Virtual Healthcare Conference at 2:40 ET on Tuesday, November 16, 2021.

MorphoSys AG announced that Roland Wandeler, Ph.D., has decided to step down from his position as Chief Operating Officer and member of the MorphoSys Management Board effective December 31, 2021 to pursue other opportunities.

Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), today announced positive topline results from PRISM-EXT, an open-label extension of the company’s PRISM3 Phase 2 placebo-controlled trial evaluating CP101 for the prevention of recurrent C. difficile infection (CDI).

Cabaletta Bio, Inc., a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, announced that the Company will participate in two upcoming investor conferences in November.

Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, announced that the Benjamin McGraw, III, Pharm.D., Interim Executive Chairman, will participate in the following virtual investor conferences.

AnPac Bio-Medical Science Co., Ltd., a biotechnology company with operations in China and the United States focusing on early cancer screening and detection, announced it has commenced an underwritten public offering of its American Depositary Shares.